This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EPIX ESSA Pharma (EPIX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ESSA Pharma Stock (NASDAQ:EPIX) Get ESSA Pharma alerts:Sign Up Key Stats Today's Range$0.20▼$0.2050-Day Range$0.19▼$0.2452-Week Range$0.18▼$1.94VolumeN/AAverage Volume3.75 million shsMarket Capitalization$9.52 millionP/E RatioN/ADividend Yield839.96%Price TargetN/AConsensus RatingSell Company Overview ESSA Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies that target KCNQ potassium ion channels, which play a critical role in the regulation of neuronal excitability. The company’s research focuses on rare neurological and neurodevelopmental disorders driven by dysfunction in these channels. By leveraging proprietary small-molecule chemistry, ESSA Pharma aims to address underlying disease mechanisms rather than merely treating symptoms. The company’s lead candidate, EPI-589, is an orally delivered small molecule designed to upregulate KCNQ channel activity. EPI-589 is currently being evaluated in clinical trials for Temple-Baraitser syndrome and KCNQ2 developmental and epileptic encephalopathy, two ultra-rare genetic conditions characterized by severe seizures, developmental delays and motor impairments. In addition to EPI-589, ESSA Pharma maintains a preclinical pipeline of novel modulators intended to expand its portfolio into other disorders linked to KCNQ dysfunction. Founded in Canada and headquartered in Vancouver, ESSA Pharma conducts its research and clinical programs across North America and Europe. The company collaborates with leading academic institutions and patient advocacy groups to design trials that address the unique challenges of rare disease studies, including small patient populations and high unmet medical need. ESSA Pharma is led by a management team with deep expertise in neuroscience drug development, translational research and regulatory strategy. The company is publicly traded on the Nasdaq Stock Market under the ticker symbol EPIX and is committed to advancing precision therapies that have the potential to transform outcomes for patients living with rare neurological disorders.AI Generated. May Contain Errors. Read More ESSA Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreEPIX MarketRank™: ESSA Pharma scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingESSA Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageESSA Pharma has received no research coverage in the past 90 days.Read more about ESSA Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ESSA Pharma are expected to grow in the coming year, from ($0.42) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for EPIX. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipESSA Pharma is a leading dividend payer. It pays a dividend yield of 840.47%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthESSA Pharma does not have a long track record of dividend growth.Read more about ESSA Pharma's dividend. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for EPIX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders15.50% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ESSA Pharma's insider trading history. Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPIX Stock News HeadlinesInvestors in Essa Pharma Inc. (NASDAQ: EPIX) are urged to contact Siskinds LLP about its investigation into a potential class actionDecember 5, 2025 | finance.yahoo.comESSA Announces Completion of Arrangement with XenoTherapeuticsOctober 9, 2025 | prnewswire.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page. | Weiss Ratings (Ad)ESSA Securityholders Approve Acquisition by XenoTherapeuticsOctober 6, 2025 | prnewswire.comESSA Pharma Inc. (EPIX) Shareholder/Analyst Call Prepared Remarks TranscriptOctober 3, 2025 | seekingalpha.comEssa Pharma provides update on combination agreement with XenoOctober 1, 2025 | msn.comESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim OrderSeptember 30, 2025 | prnewswire.comEssa Pharma amends business combination agreement with XenoTherapeuticsSeptember 24, 2025 | msn.comSee More Headlines EPIX Stock Analysis - Frequently Asked Questions How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) released its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Builders FirstSource (BLDR) and Company Calendar Last Earnings8/13/2025Today5/05/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EPIX's financial health is in the Red zone, according to TradeSmith. EPIX has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPIX CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees50Year Founded2009Profitability EPS (Trailing Twelve Months)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.71% Return on Assets-21.22% Debt Debt-to-Equity RatioN/A Current Ratio69.06 Quick Ratio69.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.07Miscellaneous Outstanding Shares47,308,000Free Float39,975,000Market Cap$9.52 million OptionableOptionable Beta1.57 Social Links 10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:EPIX) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredTrump and Elon are BACK15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...InvestorPlace | SponsoredHow to collect $1,170/month from silverThere is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...Investors Alley | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
